Sinovac Biotech stock analysis
Want to see SVA full AI Analyst Report?
Sinovac Biotech (SVA) Stock Price & Analysis
SVA Stock Chart & Stats
- Day’s Range
- $6.25 - $6.58
- 52-Week Range
- $6.25 - $6.58
- Previous Close
- $6.47
- Volume
- N/A
- Average Volume (3M)
- 8,227
- Market Cap
- $460.27M
- Enterprise Value
- $429.15M
- Total Cash (Recent Filing)
- $11.22B
- Total Debt (Recent Filing)
- $298.98M
- Price to Earnings (P/E)
- ―
- Beta
- N/A
- Next Earnings
- May 03, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Jul 08, 2025
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
International Revenue Expansion
Rapid overseas growth is diversifying Sinovac beyond its domestic base and improving the revenue mix. Expansion across international markets can create a broader commercial platform for existing and newly approved vaccines, supporting more durable growth over the next several quarters.
Vaccine Portfolio And Pipeline
New approvals and late-stage vaccine candidates broaden the portfolio beyond established products and create additional avenues for future commercialization. Progress in rabies, enterovirus, PCV13 and meningococcal vaccines strengthens the company’s longer-term product renewal potential.
Gross Margin And Conservative Leverage
A high gross margin indicates that the vaccine portfolio retains attractive product economics, while low leverage limits debt-related pressure on the business. Together, these characteristics provide financial flexibility to support research, commercialization and international expansion.
Bears Say
Persistent Losses And Cash Burn
Deeply negative operating and free cash flow materially weaken Sinovac’s ability to fund operations and development internally. Continued cash burn, alongside recurring net losses, could force greater reliance on existing balance-sheet resources and constrain investment flexibility.
Weak And Volatile Earnings Power
The post-2021 decline shows that exceptional pandemic-era demand did not translate into consistently durable earnings power. Although revenue has stabilized and gross margins remain solid, ongoing operating losses make profitability recovery uncertain and increase execution pressure.
Governance And Filing Compliance Overhang
Ongoing regulatory monitoring and board-related litigation create governance and execution risks that can distract management from commercial priorities. Any repeat filing failure or unresolved control dispute could undermine stakeholder confidence and complicate the company’s strategic progress.
Sinovac Biotech News
SVA FAQ
What was Sinovac Biotech’s price range in the past 12 months?
What is Sinovac Biotech’s market cap?
When is Sinovac Biotech’s upcoming earnings report date?
How were Sinovac Biotech’s earnings last quarter?
Is Sinovac Biotech overvalued?
Does Sinovac Biotech pay dividends?
What is Sinovac Biotech’s EPS estimate?
How many shares outstanding does Sinovac Biotech have?
What happened to Sinovac Biotech’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Sinovac Biotech?
What is the TipRanks Smart Score and how is it calculated?
Sinovac Biotech Stock Smart Score
Company Description
Sinovac Biotech
Sinovac Biotech Ltd. is a biopharmaceutical firm primarily dedicated to the discovery, research, manufacturing, and sales of vaccines aimed at combating infectious human diseases across the People's Republic of China. Its extensive product range encompasses immunizations against Hepatitis A and B; hand, foot, and mouth disease caused by Enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza strains; coronavirus; varicella (chickenpox); and mumps. Among its commercially available vaccines are Healive, an inactivated Hepatitis A vaccine; Bilive, offering combined inactivated protection for Hepatitis A and B; Anflu, a split-virion influenza vaccine; Panflu, targeting the H5N1 influenza virus; Panflu.1, for the influenza A H1N1 virus; a mumps vaccine; another split-virion pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company further supplies a varicella vaccine; a pneumococcal polysaccharide vaccine designed to prevent Streptococcus pneumoniae infections like pneumonia and septicemia; a quadrivalent influenza vaccine providing defense against two influenza A and two influenza B viruses; and CoronaVac, its vaccine developed to address COVID-19. Additionally, Sinovac's development pipeline features a sabin inactivated polio vaccine, which has concluded Phase III clinical trials for poliomyelitis treatment, alongside a rubella vaccine candidate. The company has established several collaboration agreements, including with GlaxoSmithKline Biologicals SA for the development of measles-containing combination vaccines for the Chinese market; with Tianjin CanSino Biotechnology Inc. to advance a pneumococcal vaccine; and with Instituto Butantan to progress the Phase III clinical trials of CoronaVac, its inactivated COVID-19 vaccine candidate. Sinovac Biotech Ltd. was established in 1993 and maintains its principal offices in Beijing, China.
- Sector
- General
- Industry
- Medical - Pharmaceuticals
- CEO
- Wei Dong Yin
- Employees
- 1,959
- Website
- www.sinovacbio.com
- Address
- CN
Sinovac Biotech (SVA) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 1 | 3 | 13 |
| Technical Analysis | 1 | 3 | 1 |
| Moving Averages | 0 | 0 | 12 |







